We welcome the opportunity to respond to the comments of Patel et al. We were aware of the selective rapid degradation of p210 BCR-ABL and c-ABL after lysis of total mononuclear cells (MNCs), which has been reported previously 1 and makes assessment of p210 BCR-ABL and c-ABL protein levels in mature cell compartments difficult. In order to overcome this, we used multiple techniques to assess BCR-ABL expression in chronic myeloid leukemia (CML) cells.
more than 98% purified for CD34 ϩ cells. Therefore, we believe that the degradative activity from contaminating mature myeloid cells in these samples would be negligible. Further, in the report by Maxwell et al, 1 they found that enriching blast cells by FicollHypaque gradient centrifugation in blast crisis CML samples was sufficient to detect p210 BCR-ABL kinase activity.
We would be concerned by the results of Patel et al, 6 who failed to detect BCR-ABL protein expression in CD34 ϩ CML cells. This has never been an issue in our experience. While we find their description of a novel method to overcome the degradative activity of total MNCs using high pH to inhibit an, as yet, unidentified acid-dependent hydrolase interesting, because of the increased degradative activity in total MNCs, we would wish to see it validated in total MNCs as well as CD34 ϩ cells.
We would like to thank Patel et al for highlighting the importance of the degradative activity of total MNCs on BCR-ABL, c-ABL, and P-Tyr levels and will keep this in mind for future Western blotting experiments. 
To the editor:

Update on factor V Leiden association with venous thromboembolism in the LITE Study
In a previous article, 1 we reported population-based findings from the Longitudinal Investigation of Thromboembolism Etiology (LITE) on factor V Leiden and risk of venous thromboembolism (VTE). We used a nested case-control design (301 new VTE cases and 630 controls through 1998) from the prospective Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health Study (CHS). The odds ratio, overall, for risk of VTE for carriers of factor V Leiden was 3.67 (95% CI, 2.20-6.12). 1 We recently extended LITE to additional cases and controls through 2002. In the process, we discovered and corrected an error in the original selection of controls for ARIC that had caused us to oversample participants who had died into the control group for our earlier report. Compared with our published report, the updated sample of 502 cases and 1021 controls yielded an almost identical odds ratio for factor V Leiden of 3.46 (95% CI, 2.20-5.43). Genotype distributions and other odds ratios for factor V Leiden 
